Advanced techniques have recently been developed to account for complex challenges such as interval censoring, cured patients and treatment crossover.
TORONTO (PRWEB) April 30, 2020
Economic evaluations for health technology assessments (HTAs) often rely on estimates of “time-to-event” for patient outcomes, such as time to disease progression, time to first stroke, or time to death to assess the costs and benefits of a treatment or intervention.
Analysis of time-to-event data – also known as survival analysis – can provide estimates of survivor functions and event rates that inform these economic analyses. As well as characterising event rates over an observed period of time, such as the duration of a clinical trial, survival analysis techniques are used to extrapolate the results over a lifetime to generate estimates of mean survival benefit.
Estimates of an intervention’s cost-effectiveness can be sensitive to the methods applied in modelling and extrapolating survival data. Typically, these projections are performed using various parametric models, with each model making different assumptions about the underlying hazard function. Advanced techniques have recently been developed to account for complex challenges such as interval censoring, cured patients and treatment crossover.
For more information or to register for this event, visit Survival Analysis in HTA Submissions: A Primer.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.